Veeva Systems Inc
NYSE:VEEV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
L
|
Lakes Blue Energy NL
OTC:LKOLF
|
AU |
|
R
|
Redington Ltd
BSE:532805
|
IN |
|
E
|
Energoinstal SA
WSE:ENI
|
PL |
|
Reliance Global Group Inc
NASDAQ:EZRA
|
US |
Veeva Systems Inc
Wide
Economic Moat
Wide economic moat supported by entrenched customer lock‑in, industry‑specific intangible assets, and data/network advantages that increase value as adoption expands.
Veeva Systems Inc
Competitive Advantages
Veeva’s Data Cloud (OpenData, Veeva Network, Veeva Link/Compass) and industry content/services increase in value as more life‑science customers and datasets join, improving analytics, data quality and cross‑customer coordination. ([ir.veeva.com](https://ir.veeva.com/investors/news-and-events/latest-news/press-release-details/2025/Veeva-OpenData-and-Veeva-Network-Enable-Coordinated-Customer-Engagement-for-Boehringer-Ingelheim/default.aspx?utm_source=openai))}]} PMID:NULL}} PMID:NULL Worcestershire:NULL INTERRUPTION:NULL. Выведение закончено. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL. PMID:NULL.
Veeva’s products are deeply embedded across clinical, regulatory and commercial workflows with high dollar‑based net retention (~93%) and multi‑year migrations to its Vault CRM, creating substantial operational disruption and cost for customers to replace. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1614178/000161417825000020/q4fy25shareholderletter.htm?utm_source=openai))
Veeva has extensive life‑sciences domain expertise, compliance‑focused functionality (e.g., regulatory/submissions, eTMF, QualityDocs) and a widely adopted Vault platform that competitors find difficult to replicate. ([veeva.com](https://www.veeva.com/commercial-multichannel-crm/veeva-crm/?utm_source=openai))
Wide Economic Moat Companies
| Company | Last Price | Price Change | Market Cap | Economic Moat | ||
|---|---|---|---|---|---|---|
|
|
|
NVIDIA Corp
NVDA
|
$183.91 |
+0.9%
|
$4.5T | Wide |
|
|
|
Apple Inc
AAPL
|
$260.49 |
+2.1%
|
$3.8T | Wide |
|
|
|
Alphabet Inc
GOOGL
|
$318.49 |
-0.2%
|
$3.9T | Wide |
|
|
|
Microsoft Corp
MSFT
|
$373.07 |
+1%
|
$2.8T | Wide |
|
|
|
Amazon.com Inc
AMZN
|
$233.65 |
+1.7%
|
$2.5T | Wide |
|
|
|
Taiwan Semiconductor Manufacturing Co Ltd
2330
|
NT$1 990 |
+2.6%
|
$1.6T | Wide |
|
|
|
Meta Platforms Inc
META
|
$628.39 |
+0.1%
|
$1.6T | Wide |
|
|
|
Broadcom Inc
AVGO
|
$354.91 |
-2%
|
$1.7T | Wide |
|
|
|
Walmart Inc
WMT
|
$129.13 |
+0.6%
|
$1T | Wide |
|
|
|
Eli Lilly and Co
LLY
|
$955.19 |
-1.3%
|
$903B | Wide |
| Company | Last Price | Price Change | Market Cap | Economic Moat | ||
|---|---|---|---|---|---|---|
|
|
|
AstraZeneca PLC
AZN
|
GBX15 306 |
-0.1%
|
$320.3B | Wide |
|
|
|
Kweichow Moutai Co Ltd
600519
|
¥1 455.39 |
+1.7%
|
$264.8B | Wide |
|
|
|
Novo Nordisk A/S
NOVO B
|
kr242 |
-1.9%
|
$169.5B | Wide |
|
|
|
Zhongji Innolight Co Ltd
300308
|
¥739.14 |
+2.6%
|
$119.3B | Wide |
|
|
|
Advantest Corp
6857
|
¥24 990 |
+7.3%
|
$118.3B | Wide |
|
|
|
Eoptolink Technology Inc Ltd
300502
|
¥519.7 |
+2.7%
|
$75B | Wide |
|
|
|
Disco Corp
6146
|
¥66 890 |
+5.3%
|
$46.9B | Wide |
|
|
G
|
Gold Fields Ltd
GFI
|
Zac80 076 |
-1.5%
|
$44.9B | Wide |
|
|
|
Suzhou TFC Optical Communication Co Ltd
300394
|
¥361.96 |
-4.1%
|
$40.9B | Wide |
|
|
|
GE Healthcare Technologies Inc
GEHC
|
$72.91 |
+0%
|
$33.2B | Wide |
Veeva Systems Inc
Glance View
Veeva Systems Inc., born in the heart of Silicon Valley in 2007, embarked on its journey with a clear mission: to revolutionize the pharmaceutical and life sciences industries with cloud-based solutions. Founded by Peter Gassner, who previously held leadership roles at Salesforce and PeopleSoft, Veeva identified a niche opportunity amid the highly-regulated, complex landscape of healthcare. The company began by offering Customer Relationship Management (CRM) software tailored for the life sciences sector, allowing clients to stay compliant with industry regulations while efficiently managing relationships across the intricate healthcare network. Veeva’s CRM solutions gradually became instrumental for pharmaceutical and biotech companies in conducting their marketing, sales, and collaboration activities. As Veeva expanded, it diversified its portfolio by delving into other digital solutions, such as data management and analytics, content management, and regulatory and compliance software. Its Vault platform stood out, providing a unified suite for managing a vast array of business processes and content across powerful cloud applications. This approach enabled Veeva to serve its clientele throughout the drug development lifecycle, from research and development to commercialization. By adopting a subscription-based pricing model, Veeva ensured a steady revenue stream while continuously enhancing its offerings, solidifying its position as both a trusted partner and a critical component of its clients’ operational infrastructure. Through these strategic expansions, Veeva Systems Inc. not only adapted to the evolving demands of the healthcare sector but also reinforced its dominance in the specialized domain of life sciences cloud technology.
Our research into Economic Moat performance spans the past 10 years and focuses on companies with a wide economic moat. For this analysis, we calculated the average stock price returns of these companies, comparing them to the performance of the S&P 500 index over the same period.
The results were compelling: wide moat stocks achieved a remarkable +645% average return, compared to +188% for the broader market. This difference highlights the long-term benefits of investing in businesses that can maintain their market position and pricing power over time.
Note: This research does not account for survivorship bias. Past performance is not indicative of future results.
Economic Moat
